MedTrace Logo

Evaluation of the Efficacy and Safety of Insulin Detemir Compared With That of NPH Insulin in Subjects With Type 1 Diabetes.

NCT03220425 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 752

Last updated 2017-07-18

No results posted yet for this study

Summary

The aim of this trial is to evaluate the efficacy and safety of insulin detemir using the 2400 nmol/mL formulation to optimise dosing in subjects with type 1 diabetes on a basal (once daily)-bolus regimen.

Conditions

  • Diabetes Mellitus, Type 1

Interventions

DRUG

Insulin detemir

DRUG

NPH insulin

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-02-01
Primary Completion
2001-11-12
Completion
2001-11-12
FDA Drug
Yes

Countries

  • Australia
  • Belgium
  • Denmark
  • Finland
  • France
  • Ireland
  • Netherlands
  • Norway
  • Sweden
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03220425 on ClinicalTrials.gov